BBBoel Bengtsson

Boel Bengtsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Boel Bengtsson has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and Severity of Undetected Open-Angle Glaucoma in Persons 77 to 89 Years Old

    by Sigridur E. Oskarsdottir, Boel Bengtsson, Anders Heijl, Johan Aspberg

  • Open Access

    Impact of mono‐ or multitherapy on ocular surface health and quality of life after 5 years of follow‐up in the Glaucoma Intensive Treatment Study (GITS)

    by Gauti Jóhannesson, Christina Lindén, Johan Aspberg, Sabina Andersson‐Geimer, Anders Heijl, Boel Bengtsson, Dorothea Peters

    Aim: To evaluate the impact of initial mono‐ versus multitherapy on the ocular surface and related quality of life after 5 years follow‐up in the Glaucoma Intensive Treatment Study (GITS). Method: The study included patients with primary open‐angle glaucoma and pseudoexfoliation glaucoma who completed 5‐year follow‐up in GITS. Assessment of ocular surface disease (OSD) symptoms was done using a Swedish Translation of the OSD Index (OSDI). Signs of OSD were assessed with tear break‐up time (BUT), Schirmer I test and staining using Lissamine green. Rasch analysis was used to analyse OSDI results. Results: Data on OSD symptoms were available at 5 years in 90% (219/242) of all participants initially included in GITS. Subjective or objective OSD findings did not differ significantly between mono‐ and multitherapy. More than 90% of patients in both arms reported no or little subjective ocular surface problems and showed no or minimal staining with Lissamine green at the 60‐month visit. Furthermore, 46% had normal BUT and 60% normal Schirmer tests. Use of preservative‐free drops or need for additive lubricating tear drops did not differ between the arms. Conclusion: We found no differences in objective or subjective impact on ocular surface between the two randomization arms. However, a subgroup of glaucoma patients had more severe OSD irrespective of the amount of topical glaucoma treatment received, and this should be considered when choosing glaucoma therapy treatment in this subgroup by considering laser treatment or non‐preserved eye drops.

  • Open Access

    The Glaucoma Intensive Treatment Study (GITS): A Randomized Controlled Trial Comparing Intensive and Standard Treatment on 5 Years Visual Field Development

    by Boel Bengtsson, Anders Heijl, Johan Aspberg, Gauti Jóhannesson, Sabina Andersson-Geimer, Christina Lindén


  • Open Access

    Comparison of disease severity in glaucoma patients identified by screening in the 1990s and in routine clinical care in the 2010s in Sweden

    by B. Bengtsson, C. Villalba, D. Peters, J. Aspberg

    Background and Purpose: In a previous study comparing the amount of visual field damage at presentation in patients having open‐angle glaucoma (OAG) identified through screening and in patients diagnosed in routine clinical practice in the 1990s, the damage was considerably worse in the clinically diagnosed patients. In the present study we compare visual field damage at presentation in the same 402 screened patients with that seen in 281 newly detected previously untreated patients clinically diagnosed in the 2010s.Methods: The perimetric visual field index mean deviation (MD) was compared in the two groups of patients.Results: In the clinical patients diagnosed with bilateral visual field damage the median MD was −5.1 dB in the better eye and −13.0 dB in the worse eye. In the screened patients the median MD in the better eye was −6.5 dB and −11.5 dB in the worse eye. The differences between the clinical and screened patients were non‐significant, p = 0.28 and p = 0.67 respectively. More clinical patients had severe visual field loss, defined as MD less than −20 dB, in the worse eye than in the screened patients, 18.5% versus 12.7% respectively, p = 0.037.Conclusion: The visual field damage at presentation in clinically diagnosed OAG patients has improved in the past 20 years, but the proportion of patients with severe visual field loss in at least one eye, almost 20%, is still unacceptably high considering that severe visual field damage at presentation is the most important risk factor for later development of glaucoma blindness.


  • Open Access

    Comparison of perimetric 24‐2 and 30‐2 test patterns in detecting visual field defects in patients with tumours in the pituitary region

    by Bodil Gesslein, Magdalena Naumovska, Olof Neumann, Dimitrios Bizios, Boel Bengtsson, Peter Siesjö, Erik Uvelius, Björn Hammar, Rafi Sheikh

    Purpose: Automated perimetry provides a standardized method of measuring the visual field. The Humphrey Field Analyser (HFA) uses the 24-2 test pattern to cover 24 degrees centrally or the 30-2 test pattern to cover a slightly broader region of 30 degrees. The aim of this study was to determine whether the 24-2 test pattern provides comparable information to the 30-2 test pattern in detecting visual field defects in patients with tumours in the pituitary region.Methods: A retrospective cohort study was carried out on patients with tumours in the pituitary region and radiologically confirmed compression of the visual pathway. Included patients (79 of 133) had been examined using the Humphrey 30-2 visual field test, after which the 30-2 test patterns were reduced into corresponding 24-2 test patterns. The location of visual field defects, visual acuity and the perimetric parameters mean deviation (MD) and visual field index (VFI) were also recorded.Results: No patient was classified differently when evaluated with the 24-2 test pattern, compared to the 30-2 test pattern. Interestingly, although the majority of patients had visual field defects located in the temporal visual field of each eye, a significant minority did not. In addition, it was found that a large proportion of patients had normal visual acuity (=0.8).Conclusions: The use of the HFA 24-2 test pattern reliably detected visual field defects in patients with tumours in the pituitary region. The present study indicates that MD and VFI are not reliable parameters for evaluating visual field defects due to compression.


  • Open Access

    Long‐term follow‐up of laser trabeculoplasty in multi‐treated glaucoma patients

    by Erika Rasmuson, Boel Bengtsson, Christina Lindén, Anders Heijl, Johan Aspberg, Sabina Andersson‐Geimer, Gauti Jóhannesson

    Purpose: To evaluate the long-term effect of laser trabeculoplasty (LTP) in patients randomized to multi-treatment in the Glaucoma Intensive Treatment Study (GITS). Methods: Patients with untreated newly diagnosed open-angle glaucoma were treated with three intraocular pressure (IOP)-lowering substances for 1 week and then 360 degrees argon or selective LTP was performed. IOP was measured just before LTP and repeatedly during the 60-month study period. Our previous report on 12 months follow-up data revealed no effect of LTP in eyes having an IOP = 15 mmHg; 2.6 +/- 3.1 mmHg at 1 month and 1.7 +/- 2.8 mmHg at 48 months, n = 56 and 48, respectively. No significant IOP reduction was seen in eyes with pre-LTP IOP = 15 mmHg, but if the pre-laser IOP was lower than that, chances of LTP success were small.


  • Open Access

    Threat to fixation and vision‐related quality of life in early open‐angle glaucoma — results from the Glaucoma Intensive Treatment Study

    by Dorothea Peters, Anders Heijl, Sabina Andersson‐Geimer, Johan Aspberg, Christina Lindén, Gauti Jóhannesson, Boel Bengtsson

    Purpose: To determine the effect of glaucomatous visual field (VF) damage close to the point of fixation, called threat‐to‐fixation (TTF), on vision‐related quality of life (VRQoL) in open‐angle glaucoma.Methods: A total of 239 patients from the Glaucoma Intensive Treatment Study (GITS) were included in this analysis. The second VF of patients with newly diagnosed primarily early glaucoma was evaluated for the presence or absence of TTF. TTF was defined as VF loss including one or more of the four innermost test points depressed at p < 1% in the total deviation probability map of Humphrey 24–2 SITA Standard visual fields. VRQoL was evaluated using Rasch‐analysed National Eye Institute Visual Function Questionnaire 25 (NEI VFQ‐25) scores. The correlation between VRQoL and TTF was evaluated using uni‐ and multivariable regression analyses.Results: TTF was present in at least one eye in 115 patients (48%); located in the superior hemifield alone in 47% (54 of 115), in the inferior hemifield alone in 23% (27 of 115), and in 30% (34 of 115) in both hemifields. The median Rasch‐calibrated NEI VFQ‐25 scores were identical when comparing patients with TTF (VRQoL score 66, 95% CI: 23–100) and those with no‐TTF (VRQoL score 66, 95% CI: 21–100) (p = 0.925). Neither the presence of TTF (R2 = −0.004, p = 0.968) nor the location of TTF (R2 = 0.023, p = 0.103) was significantly correlated to Rasch‐calibrated NEI VFQ‐25 scores.Conclusion: The presence of TTF did not influence VRQoL, as measured by the NEI‐VFQ‐25, in this relatively large group of patients with mainly early glaucoma.


  • Open Access

    The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial

    by Boel Bengtsson, Christina Lindén, Anders Heijl, Sabina Andersson‐Geimer, Johan Aspberg, Gauti Jóhannesson

    Purpose: The aim of the study was to determine the perimetric rate of glaucoma progression in the ongoing Glaucoma Intensive Treatment Study (GITS) after 3 years of follow‐up.Design: This is a randomized, two‐centre, prospective open‐labelled treatment trial for open‐angle glaucoma (OAG).Participants: The participants of this study were treatment‐naive patients with newly diagnosed OAG, aged 46–78 years, with early to moderate glaucomatous visual field loss scheduled to be followed for 5 years within the study.Methods: Patients were randomized to initial treatment with either topical monotherapy or with an intensive approach using drugs from three different classes, plus 360° laser trabeculoplasty. Changes in treatment were allowed. Standard automated perimetry and tonometry were performed and side‐effects documented. All results are presented using intention‐to‐treat analysis.Results: A total of 242 patients were randomized. After 3 years of follow‐up, eight patients were lost to follow‐up, six of whom were deceased. The median untreated baseline intraocular pressure (IOP) was 24 mmHg in both arms. The median IOP was almost constant over the 3 years of follow‐up: ≈17 mmHg in the mono‐arm and ≈14 mmHg in the multi‐treatment arm. Treatment was intensified in 42% of the mono‐treated patients and in 7% of the multi‐treated patients. Treatment was reduced in 13% of the multi‐treated patients. The median perimetric rate of progression was −0.5%/year in the mono‐treated group and −0.1%/year in the multi‐treated group (p = 0.03).Conclusion: The rate of disease progression was significantly slower in the multi‐treated patients than in the mono‐treated patients. Further follow‐up will show whether this difference is sustained over time.


  • Laser trabeculoplasty in newly diagnosed multi‐treated glaucoma patients

    by Erika Rasmuson, Boel Bengtsson, Christina Lindén, Anders Heijl, Johan Aspberg, Sabina Andersson‐Geimer, Gauti Jóhannesson

    Purpose: To evaluate the intraocular pressure (IOP)‐lowering effect of laser trabeculoplasty (LTP) in eyes which IOP had been substantially reduced by intensive topical treatment for one week.Methods: Patients with newly diagnosed open‐angle glaucoma were randomized to treatment with three IOP‐lowering substances. One week later, 360° argon or selective LTP was performed. IOP was measured before LTP and at one‐, three‐, six‐ and 12‐month post‐LTP. The patients were part of the Glaucoma Intensive Treatment Study (GITS).Results: Mean IOP (± SD) in 152 eyes of 122 patients was 14.0 (± 3.5) mmHg just before LTP. For every mmHg higher IOP prior to LTP, the IOP was reduced by an additional 0.6 mmHg at 12 months. The IOP was significantly reduced at all follow‐up visits from −2.6 (± 3.1) mmHg at one month to −2.1 (± 3.8) mmHg at 12 months in eyes with pre‐LTP IOP ≥ 15 mmHg, while no significant IOP reduction was seen in eyes with pre‐LTP IOP < 15 mmHg. Older age, argon LTP and male sex were associated with larger IOP reduction after 12 months, whereas presence of exfoliation syndrome was associated with a smaller IOP reduction. No severe complications were reported.Conclusion: Success of LTP was highly dependent on the IOP level prior to LTP treatment. A sustained significant IOP reduction was seen in eyes with pre‐LTP IOP ≥ 15 mmHg whereas no such effect was seen in eyes with pre‐LTP IOP < 15 mmHg. Thus, LTP can be considered in eyes with multi‐treatment when target pressure of < 15 mmHg is not achieved.